NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) revolutionary DehydraTECH™ technology has proven to be effective in cannabinoid delivery and is now undergoing testing for nicotine. An article discussing the company reads: “Lexaria is now looking to out-license its DehydraTECH to third-party partners in the tobacco industry. These partnerships could pave the way for a healthier smoke-free option for the one billion smokers worldwide. Lexaria is the only company in the world that holds a patent for this oral technology, including the pill. A new U.S. patent award protects this nicotine delivery system, creating a path for what could be the world’s first nicotine edibles for the smokeless tobacco industry.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer